Cellectis S.A. (CLLS)

Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT

NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today will present its first research data on the development of a novel universal CAR T-cell with immune-evasive properties using TALEN®-gene editing, at the American Society of Cell and Gene Therapy Annual Meeting (ASGCT) being held on May 16-19, 2022. This

• 
  Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting

  GlobeNewswire
• 
  VectorY Announces Preclinical Data on TDP-43 and Oxidized Phospholipids at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

  Business Wire

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022

◦ UCART20x22 preclinical data presented at AACR demonstrated PoC with robust in vitro and in vivo anti-tumor activity ◦ Published two articles in Nature Communications providing preclinical validation for the evaluation of UCART123 to treat AML and BPDCN ◦ Received a $20 million convertible note under collaboration agreement with its partner Cytovia Therapeutics ◦ The US FDA has allowed an IND to proceed for Iovance Biotherapeutics’ first genetically modified TIL therapy, which is leveraging TAL

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights04/30/202245,510,81051,103,431 About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunother